Ndings consistent with the new onset of myopericarditis, a standardized, protocol-defined, cardiac evaluation was completed. 2.3. Clinical laboratory evaluations Complete blood counts, blood chemistries and tests to detect myopericarditis were performed in clinical laboratories at each study site. CD4 and CD8 T-cell counts, and the activation states of CD8 T-cells (HLA-DR and CD38 expression), wer
Ndings consistent with the new onset of myopericarditis, a standardized, protocol-defined, cardiac evaluation was completed. 2.3. Clinical laboratory evaluations Complete blood counts, blood chemistries and tests to detect myopericarditis were performed in clinical laboratories at each study site. CD4 and CD8 T-cell counts, and the activation states of CD8 T-cells (HLA-DR and CD38 expression), wer
Tudy exclusion criteria included chronic neurological disorder, head injury, uncontrolled seizure disorder, experimental drugs or vaccination within the past 15 days, radiation or chemotherapy within prior month, mental condition involving inability to understand, chronic alcohol or drug abuse, pregnancy, opportunistic infection, cancer, medical condition (heart, liver or kidney) or MR contraindic
Ministered to HIV-infected young adults on highly active antiretroviral therapy (HAART).NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript2.2. Vaccine2. Materials and methodsThis was a prospective, multicenter trial carried out by the Pediatric AIDS Clinical Trials Group (PACTG) and the International Maternal, Pediatric, Adolescent, AIDS Clinical Trials (IMPAACT) network. T
Hile the magnitude of vaccine-specific CD4 and CD8 T cell responses is likely to relate to vaccine effectiveness, functional properties of vaccine-elicited responses may also be important. In our studies, significant increases in CD4 T cell proliferation and CD8 T cell IFN production were detected. Direct comparisons of the frequencies and magnitude of vaccine-elicited responses are difficult due
S did not count as first-line failures. The decision to switch to a second-line bPI-containing regimen for first-line failure was based on clinical criteria in both groups (new/ recurrent WHO 4 event (per-protocol); or single or multiple WHO 3 events at clinician discretion), or confirmed CD4,100 cells/ mm3 on ART (,50 cells/mm3 before July 2006) for LCM. Switching was discouraged before 48 weeks
S did not count as first-line failures. The decision to switch to a second-line bPI-containing regimen for first-line failure was based on clinical criteria in both groups (new/ recurrent WHO 4 event (per-protocol); or single or multiple WHO 3 events at clinician discretion), or confirmed CD4,100 cells/ mm3 on ART (,50 cells/mm3 before July 2006) for LCM. Switching was discouraged before 48 weeks
And clinical failure criteria, they were counted as immunological failures. Where CDM participants had both WHO 4 and WHO 3 events, they were counted as WHO 4 failures. Categorical variables were compared using chi-squared/exact tests, continuous variables using t-tests/rank-sum tests. To inform clinical practice when `tiebreaker' VL tests are not available to confirm that clinical/immunological f